StockNYSE · US · USDHealthcare · Medical Instruments & Supplies
$NVST
Envista Holdings Corp
Envista is a global dental products company serving dental professionals in over 130 countries, including specialists, general dentists, dental laboratories, dental service organizations, and other oral health providers. It operates through two segments: Specialty Products & Technologies, which includes dental implants and orthodontics, and Equipment & Consumables, which includes diagnostic and consumable dental products. Its brands include Nobel Biocare, Ormco, DEXIS, and Kerr. Envista develops, manufactures, and markets dental implant systems, prosthetics, orthodontic products, imaging equipment and software, restorative and endodontic products, infection prevention supplies, and other dental tools. It sells directly to dental professionals and through distribution partners. Sales of consumable products, services, and spare parts comprised approximately 85% of its 2025 sales. Envista is headquartered in Brea, California.
Envista Holdings Corporation (NYSE: NVST) priced a $430 million offering of 6.250% Senior Notes due 2033 at 99.482% of the principal amount. The offering is expected to close by November 24, 2026. Proceeds will repay a term loan and cover general corporate purposes. J.P. Morgan, BofA Securities, and Wells Fargo Securities are active bookrunners.
UBS kept its Neutral rating on Envista Holdings but raised its price target to $29 from $27, suggesting a 16.2% upside from the Nov 5 close of $24.96. Recent analyst price targets for the company range from $26 to $32.
Envista Holdings (NVST) raised its 2026 earnings outlook, reporting Q3 adjusted EPS of $0.40 (beating estimates) and revenue of $691.5M. Growth was driven by productivity and pricing, but China's VBP reforms may pressure 2027 margins. NVST expects continued margin expansion and product commercialization.
via TradingView
NVST sentiment & insider activity
Recent NVST coverage spans financial news, earnings and corporate actions.
What's driving NVST
The note pricing adds debt but provides cash to reduce existing loan, likely neutral to modestly positive for equity.
Evercore ISI Group raised its price target for Envista Holdings to $30, up from $28, while maintaining an Outperform rating. This implies a 10.3% upside from the Nov 4 close of $27.19. Recent analyst price targets for the company range from $26 to $32.
AlphAI scores every news story that mentions NVST with an AI model for sentiment and relevance, and aggregates insider trades from Envista Holdings Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Envista Holdings Corporation (NYSE: NVST) priced a $430 million offering of 6.250% Senior Notes due 2033 at 99.482% of the principal amount. The offering is expected to close by November 24, 2026. Proceeds will repay a term loan and cover general corporate purposes. J.P. Morgan, BofA Securities, and Wells Fargo Securities are active bookrunners.
UBS kept its Neutral rating on Envista Holdings but raised its price target to $29 from $27, suggesting a 16.2% upside from the Nov 5 close of $24.96. Recent analyst price targets for the company range from $26 to $32.
Envista Holdings (NVST) raised its 2026 earnings outlook, reporting Q3 adjusted EPS of $0.40 (beating estimates) and revenue of $691.5M. Growth was driven by productivity and pricing, but China's VBP reforms may pressure 2027 margins. NVST expects continued margin expansion and product commercialization.
Evercore ISI Group raised its price target for Envista Holdings to $30, up from $28, while maintaining an Outperform rating. This implies a 10.3% upside from the Nov 4 close of $27.19. Recent analyst price targets for the company range from $26 to $32.
Envista Holdings (NYSE: NVST) reported Q3 2026 sales of $691M, up 2.7% year-over-year. GAAP EPS was $3.11, adjusted EPS $0.40. Adjusted EBITDA grew 9% to $106M. The company raised full-year guidance, citing strong momentum. It repurchased 386K shares for $10M and has $273M remaining in its buyback program.
Envista Holdings Corp. reports Q3 earnings, with analysts expecting $0.36 EPS on $688.8M revenue, down from Q2 due to China's orthodontic procurement policies. Full-year guidance remains unchanged. Analysts maintain a Buy rating with a $28.69 price target, but recent downgrades cite China headwinds. Investors will watch for commentary on China's impact and margin trends.
Envista Holdings Corporation (NVST) released its 2025 Sustainability Report, highlighting progress in dental care access, employee support, environmental efficiency, and governance. Key achievements include a 40% reduction in waste, 19% reduction in water use, $2.4M donated to the Envista Smile Project, and a 17% decrease in lost time injuries. The report outlines performance and future improvement opportunities.
Henry Schein (HSIC) reported Q2 revenues of $3.46B, up 6.7% YoY, beating estimates. Envista (NVST) saw 7.1% YoY growth, while Align Tech (ALGN) and Dentsply Sirona (XRAY) reported mixed results. Sector stocks are down 18.3% on average since earnings.
Analysts downgraded several companies: Baird's Jeff Johnson cut Envista (NVST) to Neutral, Cirrus Logic (CRUS) to Equal-Weight, and Align Tech (ALGN) to Neutral. Goldman's Ronald Keung downgraded ZTO Express (ZTO) to Neutral. Goldman's Neil Mehta downgraded Par Pacific (PARR) to Neutral. Price targets were also adjusted.
Analysts updated ratings for healthcare companies. Piper Sandler maintained a Hold on Envista (NVST) with a $26 target. Bristol-Myers (BMY) received a Buy rating and $82 target from Piper Sandler. Bank of America reiterated a Buy on Eli Lilly (LLY) with a $1341 target.